GSK names Luke Miels as CEO designate, effective January 2026
PositiveFinancial Markets

GSK has announced the appointment of Luke Miels as CEO designate, set to take effect in January 2026. This decision marks a significant step for the company as it prepares for a new leadership era. Miels, who has been with GSK for several years, is expected to bring fresh perspectives and strategies to the role, which is crucial for the company's future growth and innovation in the pharmaceutical industry.
— Curated by the World Pulse Now AI Editorial System